Clinical Trial Update: Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa [Phase 3]

View source ↗

Summary

Phase 3 study evaluating ALXN1850 in pediatric patients with hypophosphatasia who were previously treated with asfotase alfa; the trial is active but not curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypophosphatasia

Drugs mentioned

• ALXN1850 (ALXN1850)
• STRENSIQ (asfotase alfa)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Hypophosphatasia | Phase 3 | Status: ACTIVE_NOT_RECRUITING